54023-00-6

Upstream product

• 88-14-2 2-furanoic acid 
• 626-43-7 3,5-Dichloroaniline 
• 98-01-1 furfural 

Downstream Products

• 1403473-47-1 N-{3-[3-(tert-butoxycarbonylamino)benzyl]-2,4-dioxoimidazolidin-1-yl}-5-(3,5-dichlorophenyl)-2-furamide 
• 1403473-79-9 N-{3-[4-(tert-butoxycarbonylamino)benzyl]-2,4-dioxoimidazolidin-1-yl}-5-(3,5-dichlorophenyl)-2-furamide 
• 1403473-16-4 5-(3,5-dichlorophenyl)-N-{2,4-dioxo-3-[(pyridin-4-yl)methyl]imidazolidin-1-yl}-2-furamide 
• 1403472-97-8 N-[3-(3-aminobenzyl)-2,4-dioxoimidazolidin-1-yl]-5-(3,5-dichlorophenyl)-2-furamide 
• 1403473-11-9 N-[3-(4-aminobenzyl)-2,4-dioxoimidazolidin-1-yl]-5-(3,5-dichlorophenyl)-2-furamide hydrochloride 
• 1403473-14-2 5-(3,5-dichlorophenyl)-N-{2,4-dioxo-3-[(pyridin-3-yl)methyl]imidazolidin-1-yl}-2-furamide 
• 1403472-83-2 5-(3,5-dichlorophenyl)-N-(2,4-dioxo-3-methylimidazolidin-1-yl)-2-furamide 
• 1403473-44-8 5-(3,5-dichlorophenyl)-N-(2,4-dioxoimidazolidin-1-yl)-2-furamide 

Relevant academic research and scientific papers

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generatin

Small-molecular inhibitors of Ca2+-induced mitochondrial permeability transition (MPT) derived from muscle relaxant dantrolene

A structure consisting of substituted hydantoin linked to a 5-(halophenyl)furan-2-yl group via an amide bond was identified as a promising scaffold for development of low-molecular-weight therapeutic agents to treat vascular dysfunction, including ischemia/reperfusion injury. Among the compounds synthesized, 5-(3,5-dichlorophenyl)-N-{2,4-dioxo-3-[(pyridin-3-yl)methyl] imidazolidin-1-yl}-2-furamide (17) possessed the most potent inhibitory activity against Ca2+-induced mitochondrial swelling. The structural development, synthesis and structure-activity relationship of these compounds are described.

EP2 RECEPTOR AGONISTS

A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).